Abbreviated New Drug Application Litigation, Number Of Notices Received

No definition available.

Name:	espr_AbbreviatedNewDrugApplicationLitigationNumberOfNoticesReceived
Namespace Prefix:	espr_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage Of Risk Reduction

+ References

No definition available.

+ Details

Name:	espr_PercentageOfRiskReduction
Namespace Prefix:	espr_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Potential Proceeds From Partner Milestone Payments

+ References

No definition available.

+ Details

Name:	espr_PotentialProceedsFromPartnerMilestonePayments
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Settlement Agreement Aggregate First Milestone Payment From Partner

+ References

No definition available.

+ Details

Name:	espr_SettlementAgreementAggregateFirstMilestonePaymentFromPartner
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Settlement Agreement Aggregate Payment From Partner

+ References

No definition available.

+ Details

Name:	espr_SettlementAgreementAggregatePaymentFromPartner
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Settlement Agreement Aggregate Second Milestone Payment From Partner

+ References

No definition available.

+ Details

Name:	espr_SettlementAgreementAggregateSecondMilestonePaymentFromPartner
Namespace Prefix:	espr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Settlement Agreement, Time Required to Pay Cash Portion of Settlement

+ References

No definition available.

+ Details

Name:	espr_SettlementAgreementTimeRequiredToPayCashPortionOfSettlement
Namespace Prefix:	espr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	espr_TypeOfRiskAxis=espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	espr_TypeOfRiskAxis=espr_CardiovascularRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) $ in Millions			4 Months Ended
Commitments and Contingencies (Details) $ in Millions	Jan. 02, 2024 USD ($)	Mar. 27, 2023 USD ($)	Jun. 30, 2024 company
Loss Contingencies [Line Items]
First milestone payment	$ 100.0
Time required to pay cash portion	15 days
Second milestone payment	$ 25.0
Number of notices received from pharmaceutical companies \| company			9
Minimum
Loss Contingencies [Line Items]
Aggregate payment agreement	$ 125.0
Cardiovascular Risk Outcome Less than Twenty Percent \| Minimum
Loss Contingencies [Line Items]
Partner milestone payments		$ 300.0
Cardiovascular Risk \| Minimum
Loss Contingencies [Line Items]
Percentage of risk reduction		20.00%